Bristol Myers Squibb sets October 29 results date. Bristol Myers Squibb stock costs EUR 55.12

Published on 10/27/2026 at 16:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bristol Myers Squibb reports October 29 after second-quarter revenue of USD 12.97 billion. Bristol Myers Squibb stock costs EUR 55.12 on October 27, 2026.

Reporting date and operating figures

Bristol Myers Squibb is scheduled to report results on October 29, 2026.
Second-quarter 2026 revenue reached USD 12.97 billion, up 6.00 percent year over year.
Bristol Myers Squibb stock costs EUR 55.12 at Lang & Schwarz on October 27, 2026 at 4:32 p.m. CEST.
The NYSE quote was USD 61.49 on October 27, 2026 at 11:35 a.m. ET.

Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

Bristol Myers Squibb is scheduled to publish its third-quarter results on October 29, 2026, according to Stock Analysis. The date gives investors a near-term checkpoint after the company reported second-quarter revenue of USD 12.97 billion. At Lang & Schwarz, the stock was trading at EUR 55.12 on October 27, 2026 at 4:32 p.m. CEST.

Second-quarter revenue reached USD 12.97 billion

TickerScout reported that Bristol Myers Squibb's second-quarter 2026 revenue rose 6.00 percent year over year to USD 13.0 billion, while Growth Portfolio revenue increased 15.00 percent to USD 7.6 billion. The standardized statement figure for the quarter was USD 12.97 billion, with consolidated net income of USD 3.316 billion and diluted earnings per share of USD 1.62.

The revenue result matters because the Growth Portfolio supplied the faster expansion within the reported quarter. Bristol Myers Squibb's second-quarter 2026 total assets stood at USD 87.634 billion, while operating cash flow reached USD 3.393 billion for the same period.

How does the stock compare?

The primary-market quote was USD 61.49 on the NYSE on October 27, 2026 at 11:35 a.m. ET. Bristol Myers Squibb had a market capitalization of USD 125.6 billion, a trailing price-to-earnings ratio of 13.51 and a 52-week range of USD 42.52 to USD 68.64.

Johnson & Johnson traded at USD 268.42 against a previous session close of USD 266.30, a gain of 0.80 percent, with a market capitalization of USD 646.2 billion and a price-to-earnings ratio of 40.70. Pfizer traded at USD 29.80 against USD 29.79, up 0.03 percent, with a market capitalization of USD 169.9 billion and a price-to-earnings ratio of 39.36.

October 29 is the next checkpoint

The upcoming results can provide a fresh update on revenue growth, operating cash flow and the contribution from the Growth Portfolio. The company website identifies the NYSE listing as BMY and describes oncology, hematology, neuroscience, immunology and cardiovascular medicines as its main therapeutic areas.

Stock stays below its yearly high

Bristol Myers Squibb stock was trading at EUR 55.12 at Lang & Schwarz on October 27, 2026 at 4:32 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Bristol Myers Squibb stock.